Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer
about
Negative feedback regulation of the ERK1/2 MAPK pathwayMitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant TransformationInduction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant CellsDifferentiated thyroid cancer-personalized therapies to prevent overtreatment.DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer.
P2860
Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinical and therapeutic impli ...... itive papillary thyroid cancer
@ast
Clinical and therapeutic impli ...... itive papillary thyroid cancer
@en
type
label
Clinical and therapeutic impli ...... itive papillary thyroid cancer
@ast
Clinical and therapeutic impli ...... itive papillary thyroid cancer
@en
prefLabel
Clinical and therapeutic impli ...... itive papillary thyroid cancer
@ast
Clinical and therapeutic impli ...... itive papillary thyroid cancer
@en
P2860
P50
P1433
P1476
Clinical and therapeutic impli ...... itive papillary thyroid cancer
@en
P2093
Linda A Dultz
Shumon Dhar
P2860
P304
1239-44; discussion 1244-5
P356
10.1016/J.SURG.2013.06.024
P407
P577
2013-10-02T00:00:00Z